ATE547404T1 - Piperidinderivate - Google Patents
PiperidinderivateInfo
- Publication number
- ATE547404T1 ATE547404T1 AT04787951T AT04787951T ATE547404T1 AT E547404 T1 ATE547404 T1 AT E547404T1 AT 04787951 T AT04787951 T AT 04787951T AT 04787951 T AT04787951 T AT 04787951T AT E547404 T1 ATE547404 T1 AT E547404T1
- Authority
- AT
- Austria
- Prior art keywords
- disorder
- sleep
- insomnia
- system diseases
- histamine
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 7
- 208000035475 disorder Diseases 0.000 abstract 4
- 208000019116 sleep disease Diseases 0.000 abstract 4
- 208000020685 sleep-wake disease Diseases 0.000 abstract 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 206010022437 insomnia Diseases 0.000 abstract 3
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 abstract 2
- 206010015037 epilepsy Diseases 0.000 abstract 2
- 239000003395 histamine H3 receptor antagonist Substances 0.000 abstract 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract 2
- 230000003252 repetitive effect Effects 0.000 abstract 2
- 230000007958 sleep Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 1
- 208000017164 Chronobiology disease Diseases 0.000 abstract 1
- 206010012218 Delirium Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000027534 Emotional disease Diseases 0.000 abstract 1
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061216 Infarction Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000012898 Olfaction disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010034018 Parosmia Diseases 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000001476 alcoholic effect Effects 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003792 electrolyte Substances 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 201000003995 melancholia Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 229960005181 morphine Drugs 0.000 abstract 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 230000003533 narcotic effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000035824 paresthesia Diseases 0.000 abstract 1
- 230000000737 periodic effect Effects 0.000 abstract 1
- 208000027232 peripheral nervous system disease Diseases 0.000 abstract 1
- -1 piperidine derivative compound Chemical class 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003330758 | 2003-09-22 | ||
| PCT/JP2004/013768 WO2005028438A1 (ja) | 2003-09-22 | 2004-09-21 | 新規ピペリジン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE547404T1 true ATE547404T1 (de) | 2012-03-15 |
Family
ID=34373028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04787951T ATE547404T1 (de) | 2003-09-22 | 2004-09-21 | Piperidinderivate |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7547693B2 (de) |
| EP (1) | EP1669350B1 (de) |
| JP (1) | JP4765627B2 (de) |
| CN (1) | CN1902177A (de) |
| AT (1) | ATE547404T1 (de) |
| AU (1) | AU2004274309B2 (de) |
| CA (1) | CA2551037A1 (de) |
| WO (1) | WO2005028438A1 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030236259A1 (en) * | 2002-02-05 | 2003-12-25 | Rolf Hohlweg | Novel aryl- and heteroarylpiperazines |
| ATE547404T1 (de) * | 2003-09-22 | 2012-03-15 | Msd Kk | Piperidinderivate |
| SE0401971D0 (sv) * | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidne derivatives |
| EP1707203A1 (de) * | 2005-04-01 | 2006-10-04 | Bioprojet | Verwendung von Alkylaminen, die kein Imidazole enthalten, als Histamin H3 Rezeptor Liganden, zur Behandlung von Morbus Parkinson, obstruktiver Schlafapnoe, vaskularer Demenz, Demenz mit Lewy Korpen |
| BRPI0610580B8 (pt) * | 2005-05-30 | 2021-05-25 | Banyu Pharma Co Ltd | composto derivado de piperidina |
| MX2007015675A (es) * | 2005-07-04 | 2008-02-20 | Novo Nordisk As | Antagonistas del receptor de histamina h3. |
| RU2442775C2 (ru) * | 2005-07-04 | 2012-02-20 | Хай Пойнт Фармасьютикалс, ЛЛС | Антагонисты гистаминовых н3-рецепторов |
| US8158673B2 (en) * | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| TWI385169B (zh) * | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
| ES2381205T3 (es) * | 2005-11-10 | 2012-05-24 | Msd K.K. | Derivado espiro aza-sustituido |
| KR20090014347A (ko) | 2006-04-07 | 2009-02-10 | 하이 포인트 파마슈티칼스, 엘엘씨 | 11β-히드록시스테로이드 탈수소효소 타입 1 활성 화합물 |
| EP2402324A1 (de) * | 2006-05-29 | 2012-01-04 | High Point Pharmaceuticals, LLC | Benzodioxolylcyclopropylpiperazinylpyridazine |
| EP1878721A1 (de) * | 2006-07-13 | 2008-01-16 | Novo Nordisk A/S | 4-Piperidylbenzamide als Inhibitoren der 11-beta-hydroxysteroiddehydrogenase Typ 1 |
| WO2008006702A1 (en) | 2006-07-13 | 2008-01-17 | High Point Pharmaceuticals, Llc. | 11beta-hydroxysteroid dehydrogenase type 1 active compounds |
| KR101313804B1 (ko) | 2007-03-20 | 2013-10-01 | 쿠리스 인코퍼레이션 | Ｈｓｐ９０ 억제제로서의 융합된 아미노 피리딘 |
| ES2373255T3 (es) | 2007-05-04 | 2012-02-01 | Astrazeneca Ab | Proceso para s�?ntesis de �?cidos alquilfosf�?nicos mediante iniciación de una amina y un aminóxido. |
| AU2008258599B2 (en) * | 2007-06-05 | 2013-06-13 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
| AU2008258597A1 (en) * | 2007-06-05 | 2008-12-11 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
| EP2014656A3 (de) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | Neue heterocyclische H3-Antagonisten |
| WO2009049157A1 (en) * | 2007-10-11 | 2009-04-16 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
| JP2011510996A (ja) * | 2008-01-30 | 2011-04-07 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規ｓＥＨ阻害剤およびその使用 |
| WO2009097475A1 (en) * | 2008-01-30 | 2009-08-06 | Smithkline Beecham Corporation | NOVEL sEH INHIBITORS AND THEIR USE |
| US20100311776A1 (en) * | 2008-01-30 | 2010-12-09 | Smithkline Beecham Corporation | Novel sEH Inhibitors and their Use |
| AR074467A1 (es) * | 2008-12-05 | 2011-01-19 | Sanofi Aventis | Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras. |
| AR074466A1 (es) | 2008-12-05 | 2011-01-19 | Sanofi Aventis | Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3. |
| EP2387316A4 (de) | 2009-01-16 | 2012-06-13 | Curis Inc | Kondensierte aminopyridine zur behandlung von hirntumoren |
| WO2011143148A1 (en) | 2010-05-11 | 2011-11-17 | Sanofi | Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
| EP2569297A1 (de) | 2010-05-11 | 2013-03-20 | Sanofi | Substituierte n-heterocycloalkyl-bipyrrolidinphenylamidderivate, ihre zubereitung und therapeutische verwendung |
| AR081498A1 (es) | 2010-05-11 | 2012-09-19 | Sanofi Aventis | Derivados de n-alquil -y n-acil-tetrahidroisoquinolina sustituidos, preparacion y su uso terapeutico de los mismos |
| EP2569294B1 (de) * | 2010-05-11 | 2015-03-11 | Sanofi | Substituierte n-heteroaryl bipyrrolidin carboxamiden , deren herstellung und therapeutische verwendung |
| TW201206444A (en) * | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted N-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof |
| EP2569280B1 (de) | 2010-05-11 | 2015-02-25 | Sanofi | Substituierte Phenyl-Cycloalkyl-Pyrrolidin- (Piperidin)-Spirolactame und -amide, ihre Herstellung und therapeutische Verwendung |
| PE20130774A1 (es) | 2010-07-29 | 2013-06-26 | Rigel Pharmaceuticals Inc | Compuestos heterociclicos activadores de ampk y metodos para emplearlos |
| WO2013130943A1 (en) * | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Alkyl-and di-substituted amido-benzyl sulfonamide derivatives |
| WO2013130935A1 (en) * | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Amido-benzyl sulfoxide derivatives |
| WO2014028829A1 (en) * | 2012-08-16 | 2014-02-20 | The Scripps Research Institute | Novel kappa opioid ligands |
| WO2017083219A1 (en) * | 2015-11-12 | 2017-05-18 | Merck Sharp & Dohme Corp. | Bispiperidinyl derivatives as liver x receptor beta agonists, compositions, and their use |
| WO2018068297A1 (en) * | 2016-10-14 | 2018-04-19 | Merck Sharp & Dohme Corp. | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE |
| WO2018068296A1 (en) | 2016-10-14 | 2018-04-19 | Merck Sharp & Dohme Corp. | PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE |
| KR20230040953A (ko) * | 2020-07-17 | 2023-03-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 치환된 피페리딘 화합물 및 이의 적용례 |
| JP7591592B2 (ja) * | 2022-01-14 | 2024-11-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 置換ピペリジン化合物を含有する医薬 |
Family Cites Families (183)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3914250A (en) | 1974-08-01 | 1975-10-21 | American Home Prod | 1,4-Diazepino{8 6,5,4-jk{9 carbazoles |
| US3951982A (en) * | 1974-11-21 | 1976-04-20 | Parke, Davis & Company | Trialkylsilyl esters of 6(substituted amino)phenyl-1,-dihydro-2-oxonicotinic acid, methods for their production and conversion to the corresponding acid chlorides |
| JPS608117B2 (ja) | 1977-02-08 | 1985-02-28 | 財団法人微生物化学研究会 | 新生理活性物質エステラスチンおよびその製造法 |
| DE2928485A1 (de) | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
| US4476680A (en) | 1979-08-14 | 1984-10-16 | Sundstrand Corporation | Pressure override control |
| ZA821577B (en) | 1981-04-06 | 1983-03-30 | Boots Co Plc | Therapeutic agents |
| US4452813A (en) | 1981-05-22 | 1984-06-05 | Taiho Pharmaceutical Company Limited | Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative |
| CA1258454A (en) | 1982-08-10 | 1989-08-15 | Leo Alig | Phenethanolamines |
| IT1159765B (it) | 1982-09-28 | 1987-03-04 | Zanussi A Spa Industrie | Macchina lavabiancheria di tipo modulare |
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| IE61928B1 (en) | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
| US5391571A (en) | 1989-11-15 | 1995-02-21 | American Home Products Corporation | Cholesterol ester hydrolase inhibitors |
| US5081122A (en) | 1990-03-05 | 1992-01-14 | Sterling Drug Inc. | Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof |
| US5112820A (en) | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| US4973587A (en) | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
| US5013837A (en) | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
| US5321039A (en) | 1990-04-13 | 1994-06-14 | Societe Civile Bioprojet | Method of inducing a histamine agonist action on H2 receptors |
| ATE130851T1 (de) * | 1991-03-14 | 1995-12-15 | Basf Ag | Substituierte n-phenylpiperidine und arzneimittel daraus. |
| DE4117904A1 (de) | 1991-05-31 | 1992-12-03 | Basf Ag | Substituierte n-phenylpiperidine |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5349056A (en) | 1992-10-09 | 1994-09-20 | Regeneron Pharmaceuticals | Modified ciliary neurotrophic factors |
| US6472178B1 (en) | 1998-02-27 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof |
| US5451677A (en) | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| US5292736A (en) | 1993-02-26 | 1994-03-08 | Sterling Winthrop Inc. | Morpholinoalkylindenes as antiglaucoma agents |
| FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| US5705515A (en) | 1994-04-26 | 1998-01-06 | Merck & Co., Inc. | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity |
| WO1996011210A1 (en) * | 1994-10-07 | 1996-04-18 | Fujisawa Pharmaceutical Co., Ltd. | Cyclic hexapeptides having antibiotic activity |
| AU692977B2 (en) | 1994-11-07 | 1998-06-18 | Pfizer Inc. | Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands |
| FI973162L (fi) | 1995-01-31 | 1997-09-30 | Lilly Co Eli | Liikalihavuutta vastustavia proteiineja |
| US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| CA2211656A1 (en) | 1995-01-31 | 1996-08-08 | Margret B. Basinski | Anti-obesity proteins |
| US5554727A (en) | 1995-01-31 | 1996-09-10 | Eli Lilly And Company | Anti-obesity proteins |
| US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
| US5605886A (en) | 1995-01-31 | 1997-02-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5559208A (en) | 1995-01-31 | 1996-09-24 | Eli Lilly And Company | Anti-obesity proteins |
| US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
| FR2732017B1 (fr) | 1995-03-21 | 2000-09-22 | Inst Nat Sante Rech Med | Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques |
| US5831115A (en) | 1995-04-21 | 1998-11-03 | Abbott Laboratories | Inhibitors of squalene synthase and protein farnesyltransferase |
| US20020006964A1 (en) | 1995-05-16 | 2002-01-17 | Young James W. | Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds |
| US5739106A (en) | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| AU7626496A (en) | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Heteroaryl compounds |
| WO1997020822A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Quinazolin-2,4-diazirines as npy receptor antagonist |
| AU7692696A (en) | 1995-12-01 | 1997-06-27 | Novartis Ag | Heteroaryl derivatives |
| AU1328197A (en) | 1995-12-01 | 1997-06-19 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
| AU7692996A (en) | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Receptor antagonists |
| TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| WO1997029079A1 (en) | 1996-02-06 | 1997-08-14 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
| KR19990087055A (ko) | 1996-02-21 | 1999-12-15 | 게리 디. 스트리트, 스티븐 엘. 네스비트 | 알레르기성 질환 치료에 유용한 신규의 치환된 n-메틸-n-(4-(피페리딘-1-일)-2-(아릴)부틸)벤즈아미드 |
| IT1288388B1 (it) | 1996-11-19 | 1998-09-22 | Angeletti P Ist Richerche Bio | Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia |
| CA2274594C (en) | 1996-12-16 | 2006-10-10 | Banyu Pharmaceutical Co., Ltd. | Aminopyrazole derivatives |
| DE69822449T2 (de) | 1997-01-21 | 2005-01-27 | Smithkline Beecham Corp. | Neue cannabinoidrezeptor-modulatoren |
| US6251947B1 (en) | 1997-02-04 | 2001-06-26 | Board Of Trustees Of The University Of Arkansas | Fungicidal carboxamides |
| AU735137B2 (en) | 1997-02-21 | 2001-07-05 | Bayer Intellectual Property Gmbh | Arylsulphonamides and analogues and their use for the treatment and neurovegetative disorders |
| US5948777A (en) | 1997-03-18 | 1999-09-07 | Smithkline Beecham Corporation | Cannabinoid receptor agonists |
| FR2761265B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates |
| FR2761266B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
| DE69812096T2 (de) | 1997-04-23 | 2003-10-30 | Banyu Pharmaceutical Co., Ltd. | Neuropeptid y rezeptorantagonisten |
| US6001836A (en) | 1997-05-28 | 1999-12-14 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: cyanoguanidine derivatives |
| SE9702457D0 (sv) | 1997-06-26 | 1997-06-26 | Pharmacia & Upjohn Ab | Screening |
| KR20010021696A (ko) | 1997-07-11 | 2001-03-15 | 미즈노 마사루 | 퀴놀린 화합물 및 그의 의약용도 |
| EP1028948B1 (de) | 1997-11-07 | 2003-01-29 | Schering Corporation | Phenyl-alkyl imidazole als h3 rezeptor antagonisten |
| EP1068207A1 (de) | 1998-04-02 | 2001-01-17 | Neurogen Corporation | Aminoalkyl substituierte 9h-pyridino[2,3-b]indol- und 9h-pyrimidino[4,5-b]indol-derivate |
| BR9910583A (pt) | 1998-04-29 | 2001-01-09 | Ortho Mcneil Pharm Inc | Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios |
| US6329395B1 (en) | 1998-06-08 | 2001-12-11 | Schering Corporation | Neuropeptide Y5 receptor antagonists |
| WO1999064002A1 (en) | 1998-06-11 | 1999-12-16 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| DE19837627A1 (de) | 1998-08-19 | 2000-02-24 | Bayer Ag | Neue Aminosäureester von Arylsulfonamiden und Analoga |
| HN1998000027A (es) | 1998-08-19 | 1999-06-02 | Bayer Ip Gmbh | Arilsulfonamidas y analagos |
| US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
| US6337332B1 (en) | 1998-09-17 | 2002-01-08 | Pfizer Inc. | Neuropeptide Y receptor antagonists |
| US7417038B1 (en) | 1998-10-15 | 2008-08-26 | Imperial Innovations Limited | Methods of treating cachexia |
| IL142917A0 (en) * | 1998-11-03 | 2002-04-21 | Basf Ag | Substituted 2-phenylbenzimidazoles, the production thereof and their use |
| ATE314371T1 (de) | 1998-11-10 | 2006-01-15 | Merck & Co Inc | Spiro-indole als y5-rezeptor antagonisten |
| US6344481B1 (en) | 1999-03-01 | 2002-02-05 | Pfizer Inc. | Thyromimetic antiobesity agents |
| MXPA01009404A (es) | 1999-03-19 | 2004-03-19 | Abbott Gmbh & Co Kg | Metodo para tratar trastornos de alimentacion. |
| AU775166B2 (en) | 1999-04-22 | 2004-07-22 | H. Lundbeck A/S | Selective NPY (Y5) antagonists |
| US6340683B1 (en) | 1999-04-22 | 2002-01-22 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (triazines) |
| HK1041263A1 (zh) | 1999-05-05 | 2002-07-05 | Ortho-Mcneil Pharmaceutical, Inc. | 可用於治疗肥胖和其他疾病的3a，4，5，9b-四氢-1h-苯并[e]吲-2-基胺衍生的神经肽y受体配体 |
| AU778393B2 (en) | 1999-05-12 | 2004-12-02 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
| EP1194421B1 (de) | 1999-06-30 | 2005-10-12 | H. Lundbeck A/S | Selektive npy (y5) antagonisten |
| WO2001007409A1 (en) | 1999-07-23 | 2001-02-01 | Astrazeneca Uk Limited | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
| WO2001009120A1 (en) | 1999-07-28 | 2001-02-08 | Ortho-Mcneil Pharmaceutical, Inc. | Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders |
| TWI279402B (en) | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
| PL354784A1 (en) | 1999-09-30 | 2004-02-23 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
| ES2277855T3 (es) | 1999-09-30 | 2007-08-01 | Neurogen Corporation | Pirazolo-(1,5-a)-1,5-pirimidinas y pirazolo-(1,5-a)-1,3,5-triazinas amino sustituidas. |
| CA2379585C (en) | 1999-09-30 | 2006-06-20 | James W. Darrow | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
| WO2001027068A1 (en) | 1999-10-13 | 2001-04-19 | Pfizer Products Inc. | Biaryl ether derivatives useful as monoamine reuptake inhibitors |
| DE19949319A1 (de) | 1999-10-13 | 2001-06-13 | Ruetgers Vft Ag | Verfahren zur Herstellung von Arylalkylethern |
| US6239395B1 (en) | 1999-10-14 | 2001-05-29 | General Electric Company | Auxiliary position switch assembly for a circuit breaker |
| EP1237875B1 (de) | 1999-12-16 | 2005-08-31 | Schering Corporation | Substituierte imidazole als neuropeptide y y5 rezeptor antagonisten |
| WO2001056592A1 (en) | 2000-02-01 | 2001-08-09 | Novo Nordisk A/S | Use of compounds for the regulation of food intake |
| WO2001058869A2 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| JP2001226269A (ja) | 2000-02-18 | 2001-08-21 | Takeda Chem Ind Ltd | メラニン凝集ホルモン拮抗剤 |
| GB0004003D0 (en) | 2000-02-22 | 2000-04-12 | Knoll Ag | Therapeutic agents |
| WO2001062738A1 (en) | 2000-02-22 | 2001-08-30 | Banyu Pharmaceutical Co., Ltd. | Novel imidazoline compounds |
| US6531478B2 (en) | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| FR2805810B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| FR2805818B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| FR2805817B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| EP1132389A1 (de) | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | Neue Azaindolyl-Derivate für die Behandlung von Fettleibigheit |
| BRPI0109200B8 (pt) | 2000-03-14 | 2021-05-25 | Actelion Pharmaceuticals Ltd | compostos e composições farmacêuticas |
| JP2003527444A (ja) | 2000-03-23 | 2003-09-16 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体 |
| WO2001070708A1 (en) | 2000-03-23 | 2001-09-27 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
| US6600015B2 (en) | 2000-04-04 | 2003-07-29 | Hoffmann-La Roche Inc. | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity |
| EP1142886A1 (de) | 2000-04-07 | 2001-10-10 | Aventis Pharma Deutschland GmbH | Perzychinnin, Verfahren zu ihrer Herstellung und ihre Verwendung als pharmazeutisches Produkt |
| EP1285651B1 (de) | 2000-04-28 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Antagonisten des melanin-konzentrierenden hormons |
| GB0010757D0 (en) | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
| GB0011013D0 (en) | 2000-05-09 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
| US6432960B2 (en) | 2000-05-10 | 2002-08-13 | Bristol-Myers Squibb Company | Squarate derivatives of dihydropyridine NPY antagonists |
| US6444675B2 (en) | 2000-05-10 | 2002-09-03 | Bristol-Myers Squibb Company | 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists |
| AU2001263021A1 (en) | 2000-05-10 | 2001-11-20 | Bristol-Myers Squibb Company | Alkylamine derivatives of dihydropyridine npy antagonists |
| ATE310728T1 (de) | 2000-05-11 | 2005-12-15 | Bristol Myers Squibb Co | Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga |
| US7229986B2 (en) | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
| AUPQ761100A0 (en) | 2000-05-18 | 2000-06-08 | Australian Rural Group Limited | Lipophilic medicament |
| US6391881B2 (en) | 2000-05-19 | 2002-05-21 | Bristol-Myers Squibb Company | Thiourea derivatives of dihydropyridine NPY antagonists |
| SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| JP2003534377A (ja) | 2000-05-30 | 2003-11-18 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作働薬 |
| ES2291323T3 (es) | 2000-06-15 | 2008-03-01 | Schering Corporation | Antagonistas de receptores de trombina. |
| ES2238458T3 (es) | 2000-06-16 | 2005-09-01 | Smithkline Beecham Plc | Piperidinas para uso como antagonistas de los receptores de orexina. |
| EP1299362A4 (de) | 2000-07-05 | 2004-11-03 | Synaptic Pharma Corp | Selektive rezeptorantagonisten des melaninkonzentrierenden hormons-1 (mch1) und ihre anwendung |
| JP2004516239A (ja) | 2000-07-06 | 2004-06-03 | ニューロジェン コーポレイション | メラニン凝集ホルモン受容体リガンド |
| GB0019357D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
| CN1443198A (zh) | 2000-07-24 | 2003-09-17 | 阿达纳生物科学有限公司 | Ghrelin拮抗剂 |
| JP4180365B2 (ja) | 2000-07-31 | 2008-11-12 | エフ．ホフマン−ラ ロシュ アーゲー | ピペラジン誘導体 |
| US6768024B1 (en) | 2000-08-04 | 2004-07-27 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
| GB0019359D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
| US20040006120A1 (en) | 2000-08-21 | 2004-01-08 | Yates Stephen L | Use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity |
| US6680340B2 (en) | 2000-08-21 | 2004-01-20 | Merck & Co., Inc. | Anti-hypercholesterolemic drug combination |
| JP2004506687A (ja) | 2000-08-23 | 2004-03-04 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作働薬としての置換ピペリジン類 |
| US6900226B2 (en) | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| CA2422013A1 (en) | 2000-09-14 | 2002-03-21 | Schering Corporation | Substituted urea neuropeptide y y5 receptor antagonists |
| HUP0301351A3 (en) | 2000-10-13 | 2007-05-29 | Lilly Co Eli | Use of substituted dipeptides as growth hormone secretagogues, process for their preparation and pharmaceutical compositions containing them |
| DE10050995A1 (de) | 2000-10-14 | 2002-04-18 | Boehringer Ingelheim Pharma | Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| AU2167002A (en) | 2000-10-16 | 2002-06-11 | Hoffmann La Roche | Indoline derivatives and their use as 5-ht2 receptor ligands |
| AU2002227170A1 (en) | 2000-11-03 | 2002-05-15 | Wyeth | Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives |
| NZ525699A (en) | 2000-11-20 | 2005-03-24 | Biovitrum Ab | Piperazinylpyrazines compounds as antagonists of serotonin 5-HT2 receptor |
| CA2448729A1 (en) | 2000-11-20 | 2002-05-23 | Biovitrum Ab | Piperazinyl and piperidyl substituted heterocyclic compounds |
| EP1347982B1 (de) | 2000-12-12 | 2005-11-16 | Neurogen Corporation | Spiro[isobenzofuran-1,4'-piperidin]-3-one und 3h-spiroisobenzofuran-1,4'-piperidine |
| GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
| AU3405602A (en) | 2000-12-21 | 2002-07-01 | Schering Corp | Heteroaryl urea neuropeptide y y5 receptor antagonists |
| JP4025200B2 (ja) | 2000-12-22 | 2007-12-19 | シェーリング コーポレイション | ピペリジンｍｃｈアンタゴニストおよび肥満の処置におけるそれらの使用 |
| KR100539143B1 (ko) | 2000-12-27 | 2005-12-26 | 에프. 호프만-라 로슈 아게 | 인돌 유도체 및 그의 5-ｈｔ2ｂ 및 5-ｈｔ2ｃ 수용체리간드로서의 용도 |
| WO2002051232A2 (en) | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
| EP1368339A1 (de) | 2001-01-23 | 2003-12-10 | Eli Lilly & Company | Substituierte piperidines/piperazine als melanocortin rezeptor agonisten |
| ES2247298T3 (es) | 2001-01-23 | 2006-03-01 | Eli Lilly And Company | Derivados de piperazina y piperidina como agonistas del receptor de melanocortina. |
| CA2432988A1 (en) | 2001-01-23 | 2002-08-01 | Cristina Garcia-Paredes | Melanocortin receptor agonists |
| SK10802003A3 (sk) | 2001-02-02 | 2004-05-04 | Takeda Chemical Industries, Ltd. | Kondenzovaná heterocyklická zlúčenina, jej použitie a jej farmaceutický prípravok |
| CA2439152C (en) | 2001-02-28 | 2008-06-17 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| US7012084B2 (en) | 2001-02-28 | 2006-03-14 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| DE60215132T2 (de) | 2001-02-28 | 2007-08-23 | Merck & Co., Inc. | Acylierte piperidin-derivate als melanocortin-4-rezeptor-agonisten |
| IL157456A0 (en) | 2001-03-21 | 2004-03-28 | Pharmacopeia Inc Pharmacopeia | Aryl and biaryl compounds having mch modulatory activity |
| US6900329B2 (en) | 2001-03-21 | 2005-05-31 | Schering Corporation | MCH antagonists and their use in the treatment of obesity |
| PL363751A1 (en) | 2001-03-22 | 2004-11-29 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| JP2004532834A (ja) * | 2001-03-23 | 2004-10-28 | イーライ・リリー・アンド・カンパニー | ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用 |
| AU782148B2 (en) | 2001-03-29 | 2005-07-07 | Molecular Design International, Inc. | Beta3-adrenoreceptor agonists, agonist compositions and methods of making and using the same |
| ATE460163T1 (de) | 2001-04-12 | 2010-03-15 | Pharmacopeia Llc | Arly und diaryl piperidinderivate verwendbar als mch-hemmer |
| US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP3715280B2 (ja) | 2001-05-21 | 2005-11-09 | エフ．ホフマン−ラ ロシュ アーゲー | ニューロペプチドｙレセプターのリガンドとしてのキノリン誘導体 |
| CA2448080A1 (en) | 2001-05-22 | 2002-11-28 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
| WO2002099388A2 (en) | 2001-06-07 | 2002-12-12 | Merck & Co., Inc. | Benzodiazepine bradykinin antagonists |
| CA2450579A1 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| ES2257555T3 (es) | 2001-06-20 | 2006-08-01 | MERCK & CO., INC. | Inhibidores de dipeptidilpeptidasa para el tratamiento de la diabetes. |
| GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| CN1723196A (zh) | 2001-06-27 | 2006-01-18 | 史密丝克莱恩比彻姆公司 | 作为二肽酶抑制剂的氟代吡咯烷 |
| JPWO2003002539A1 (ja) | 2001-06-27 | 2004-10-14 | 宇部興産株式会社 | ジベンゾシクロヘプテン化合物 |
| ATE380175T1 (de) | 2001-06-27 | 2007-12-15 | Smithkline Beecham Corp | Pyrrolidine als dipeptidyl peptidase inhibitoren |
| JP4357293B2 (ja) | 2001-06-27 | 2009-11-04 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類 |
| DE60225556D1 (de) | 2001-07-03 | 2008-04-24 | Novo Nordisk As | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes |
| CA2454613A1 (en) | 2001-07-05 | 2003-01-16 | Synaptic Pharmaceutical Corporation | Substituted anilinic piperidines as mch selective antagonists |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| ITMI20011483A1 (it) | 2001-07-11 | 2003-01-11 | Res & Innovation Soc Coop A R | Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi |
| US7115628B2 (en) | 2001-07-18 | 2006-10-03 | Merck & Co., Inc. | Bridged piperidine derivatives as melanocortin receptor agonists |
| AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
| US6915444B2 (en) | 2001-09-12 | 2005-07-05 | Rockwell Automation Technologies, Inc. | Network independent safety protocol for industrial controller using data manipulation techniques |
| WO2003062234A1 (en) * | 2002-01-23 | 2003-07-31 | Yamanouchi Pharmaceutical Co., Ltd. | Quinoxaline compounds |
| EP1556046A1 (de) | 2002-10-23 | 2005-07-27 | Janssen Pharmaceutica N.V. | Phenylpiperidine und phenylpyrrolidine als histamin-h3-rezeptor-modulatoren |
| US20040192728A1 (en) * | 2003-02-03 | 2004-09-30 | Ellen Codd | Quinoline-derived amide modulators of vanilloid VR1 receptor |
| UY28506A1 (es) * | 2003-09-12 | 2005-04-29 | Basf Ag | 6-halógeno-(1,2,4)triazolo(1,5-a)pirimidinas para combatir plagas animales. |
| ATE547404T1 (de) * | 2003-09-22 | 2012-03-15 | Msd Kk | Piperidinderivate |
-
2004
- 2004-09-21 AT AT04787951T patent/ATE547404T1/de active
- 2004-09-21 CN CNA2004800273728A patent/CN1902177A/zh active Pending
- 2004-09-21 AU AU2004274309A patent/AU2004274309B2/en not_active Ceased
- 2004-09-21 JP JP2005514090A patent/JP4765627B2/ja not_active Expired - Fee Related
- 2004-09-21 EP EP04787951A patent/EP1669350B1/de not_active Expired - Lifetime
- 2004-09-21 US US10/574,087 patent/US7547693B2/en not_active Expired - Fee Related
- 2004-09-21 CA CA002551037A patent/CA2551037A1/en not_active Abandoned
- 2004-09-21 WO PCT/JP2004/013768 patent/WO2005028438A1/ja not_active Ceased
-
2009
- 2009-03-06 US US12/381,099 patent/US7834182B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20070105901A1 (en) | 2007-05-10 |
| WO2005028438A9 (ja) | 2005-05-26 |
| JPWO2005028438A1 (ja) | 2007-11-15 |
| EP1669350A4 (de) | 2009-05-06 |
| EP1669350A1 (de) | 2006-06-14 |
| US20090203710A1 (en) | 2009-08-13 |
| JP4765627B2 (ja) | 2011-09-07 |
| WO2005028438A1 (ja) | 2005-03-31 |
| US7547693B2 (en) | 2009-06-16 |
| AU2004274309B2 (en) | 2010-04-08 |
| AU2004274309A1 (en) | 2005-03-31 |
| US7834182B2 (en) | 2010-11-16 |
| CN1902177A (zh) | 2007-01-24 |
| EP1669350B1 (de) | 2012-02-29 |
| CA2551037A1 (en) | 2005-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE547404T1 (de) | Piperidinderivate | |
| FI90543B (fi) | Menetelmä lääkeaineina käyttökelpoisten dihydropyridiinin johdannaisten valmistamiseksi | |
| US5290790A (en) | 4-(4-imidazolyl) piperidines substituted at position 1, their preparation and also their therapeutic applications | |
| JP4944286B1 (ja) | シクロプロパン化合物 | |
| US9422225B2 (en) | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | |
| HK1005727B (en) | Dihydropyridine derivatives, their preparation and their use | |
| HUP0001168A2 (hu) | 5-HT4 vagy H3 receptor ligandumként használható 5-fenil-3-(piperidin-4-il)-1,3,4-oxadiazol-2(3H)-on-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| US4755512A (en) | Pharmaceutically useful dihydropyridinyldicarboxylate amides and esters incorporating arylpiperazinylalkyl moities | |
| RU2018103332A (ru) | Пиримидиновое соединение с конденсированными кольцами, его промежуточное соединение, способ получения, композиция и применение | |
| BRPI0414059A (pt) | sìntese seletiva de pirimidinas substituìdas em cf3 | |
| NZ597498A (en) | Cyclopropyl amine derivatives as histamin H3 receptor modulators | |
| CA3031621A1 (en) | Production method for pyrazole-amide compound | |
| CA2731405A1 (en) | 1,6-dihydro-2h-3-oxa-6-aza-as-indacene compounds | |
| Ban et al. | Novel antiallergic agents. Part I: Synthesis and pharmacology of pyrimidine amide derivatives | |
| US4895846A (en) | Pharmaceutically useful dihydropyridinyldicarboxylate amides and esters incorporating arylpiperazinylalkyl moieties | |
| AU708894B2 (en) | Process for the preparation of an optically pure benzofurancarboxylic acid derivative and its use for preparing efaroxan | |
| Schlegel et al. | Discovery and expanded SAR of 4, 4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists | |
| EP1948646A2 (de) | Substituierte phenylpiperidine mit serotoninerger aktivität und verbesserten therapeutischen eigenschaften | |
| EP2470022A1 (de) | Verbindungen und verfahren | |
| Ha et al. | 4-[(Pyridin-3-ylmethylene) amino] phenylhexadecanoate | |
| US4762927A (en) | Indene compounds | |
| US4992591A (en) | Preparation of alpha-(3,4-disubstituted aryl) cyclic ketones | |
| Strappaghetti et al. | Synthesis and biological affinity of new imidazo-and indol-arylpiperazine derivatives: Further validation of a pharmacophore model for α1-adrenoceptor antagonists | |
| Cheng et al. | Efficient, asymmetric synthesis of (−)-isooncinotine | |
| Delarue-Cochin et al. | Stereocontrolled access to α-fluoro-β-ketoesters |